Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City.
Department of Internal Medicine, University of Utah, Salt Lake City.
JAMA Netw Open. 2021 May 3;4(5):e215821. doi: 10.1001/jamanetworkopen.2021.5821.
Increasingly, individuals with atrial fibrillation (AF) use wearable devices (hereafter wearables) that measure pulse rate and detect arrhythmia. The associations of wearables with health outcomes and health care use are unknown.
To characterize patients with AF who use wearables and compare pulse rate and health care use between individuals who use wearables and those who do not.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, propensity-matched cohort study included 90 days of follow-up of patients in a tertiary care, academic health system. Included patients were adults with at least 1 AF-specific International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) code from 2017 through 2019. Electronic medical records were reviewed to identify 125 individuals who used wearables and had adequate pulse-rate follow-up who were then matched using propensity scores 4 to 1 with 500 individuals who did not use wearables. Data were analyzed from June 2020 through February 2021.
Using commercially available wearables with pulse rate or rhythm evaluation capabilities.
Mean pulse rates from measures taken in the clinic or hospital and a composite health care use score were recorded. The composite outcome included evaluation and management, ablation, cardioversion, telephone encounters, and number of rate or rhythm control medication orders.
Among 16 320 patients with AF included in the analysis, 348 patients used wearables and 15 972 individuals did not use wearables. Prior to matching, patients using wearables were younger (mean [SD] age, 64.0 [13.0] years vs 70.0 [13.8] years; P < .001) and healthier (mean [SD] CHA2DS2-VASc [congestive heart failure, hypertension, age ≥ 65 years or 65-74 years, diabetes, prior stroke/transient ischemic attack, vascular disease, sex] score, 3.6 [2.0] vs 4.4 [2.0]; P < .001) compared with individuals not using wearables, with similar gender distribution (148 [42.5%] women vs 6722 women [42.1%]; P = .91). After matching, mean pulse rate was similar between 125 patients using wearables and 500 patients not using wearables (75.01 [95% CI, 72.74-77.27] vs 75.79 [95% CI, 74.68-76.90] beats per minute [bpm]; P = .54), whereas mean composite use score was higher among individuals using wearables (3.55 [95% CI, 3.31-3.80] vs 3.27 [95% CI, 3.14-3.40]; P = .04). Among measures in the composite outcome, there was a significant difference in use of ablation, occurring in 22 individuals who used wearables (17.6%) vs 37 individuals who did not use wearables (7.4%) (P = .001). In the regression analyses, mean composite use score was 0.28 points (95% CI, 0.01 to 0.56 points) higher among individuals using wearables compared with those not using wearables and mean pulse was similar, with a -0.79 bpm (95% CI -3.28 to 1.71 bpm) difference between the groups.
This study found that follow-up health care use among individuals with AF was increased among those who used wearables compared with those with similar pulse rates who did not use wearables. Given the increasing use of wearables by patients with AF, prospective, randomized, long-term evaluation of the associations of wearable technology with health outcomes and health care use is needed.
越来越多的房颤(AF)患者使用可测量脉搏率和检测心律失常的可穿戴设备(后文统称可穿戴设备)。目前尚不清楚可穿戴设备与健康结果和医疗保健使用之间的关联。
描述使用可穿戴设备的 AF 患者,并比较使用可穿戴设备和未使用可穿戴设备的患者之间的脉搏率和医疗保健使用情况。
设计、环境和参与者:这是一项回顾性、倾向评分匹配的队列研究,纳入了一家三级保健、学术健康系统中 90 天的随访患者。纳入的患者为 2017 年至 2019 年至少有 1 项房颤特定的国际疾病分类第 10 次修订版(ICD-10)编码的成年人。通过电子病历来确定 125 名使用可穿戴设备且脉搏率随访充分的患者,然后使用倾向评分 4:1 与 500 名未使用可穿戴设备的患者进行匹配。数据分析于 2020 年 6 月至 2021 年 2 月进行。
使用具有脉搏率或节律评估功能的商业可穿戴设备。
记录在诊所或医院进行的测量的平均脉搏率和复合医疗保健使用评分。复合结果包括评估和管理、消融、复律、电话咨询以及节律或心率控制药物的使用次数。
在纳入分析的 16320 名 AF 患者中,348 名患者使用了可穿戴设备,15972 名患者未使用可穿戴设备。在匹配之前,使用可穿戴设备的患者更年轻(平均[标准差]年龄,64.0[13.0]岁 vs 70.0[13.8]岁;P<0.001)且更健康(平均[标准差]CHA2DS2-VASc[充血性心力衰竭、高血压、年龄≥65 岁或 65-74 岁、糖尿病、既往卒中/短暂性脑缺血发作、血管疾病、性别]评分,3.6[2.0] vs 4.4[2.0];P<0.001),与未使用可穿戴设备的患者相比,性别分布相似(148[42.5%]女性 vs 6722 名女性[42.1%];P=0.91)。匹配后,使用可穿戴设备的 125 名患者与未使用可穿戴设备的 500 名患者的平均脉搏率相似(75.01[95%置信区间,72.74-77.27] vs 75.79[95%置信区间,74.68-76.90]次/分钟[bpm];P=0.54),而使用可穿戴设备的患者的平均复合使用评分更高(3.55[95%置信区间,3.31-3.80] vs 3.27[95%置信区间,3.14-3.40];P=0.04)。在复合结果的各项措施中,使用消融术的差异有统计学意义,使用可穿戴设备的 22 名患者(17.6%)与未使用可穿戴设备的 37 名患者(7.4%)相比(P=0.001)。在回归分析中,与未使用可穿戴设备的患者相比,使用可穿戴设备的患者的平均复合使用评分高 0.28 分(95%置信区间,0.01 分至 0.56 分),且两组之间的平均脉搏率相似,差异为-0.79 bpm(95%置信区间,-3.28 至 1.71 bpm)。
本研究发现,与脉搏率相似但未使用可穿戴设备的患者相比,使用可穿戴设备的 AF 患者的后续医疗保健使用增加。鉴于房颤患者对可穿戴设备的使用不断增加,需要进行前瞻性、随机、长期评估可穿戴技术与健康结果和医疗保健使用之间的关联。